Literature DB >> 7895165

In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides.

R R Avva1, P Cresswell.   

Abstract

HLA-DR molecules associated with class II-associated invariant chain peptides (CLIP) are generated in vivo as an intermediate in class II maturation. Such complexes can be produced in vitro by proteolytic digestion of DR alpha beta I complexes, suggesting that CLIP is a residual fragment that remains associated with class II molecules following I chain degradation. In vitro, CLIP dissociation from DR alpha beta dimers occurs at different rates depending on the allele, and is facilitated by low pH and by detergents containing 8-10 carbon unbranched hydrocarbons, or by primary aliphatic amines or carboxylic acids. The accumulation of DR alpha beta CLIP complexes in HLA-DM-negative antigen-processing mutant cells argues that a functionally similar mechanism, dependent on HLA-DM expression, catalyzes in vivo CLIP dissociation and generation of normal class II-peptide complexes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7895165     DOI: 10.1016/s1074-7613(94)80018-9

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  46 in total

1.  Early endosomal maturation of MHC class II molecules independently of cysteine proteases and H-2DM.

Authors:  J A Villadangos; C Driessen; G P Shi; H A Chapman; H L Ploegh
Journal:  EMBO J       Date:  2000-03-01       Impact factor: 11.598

2.  Specific treatment of autoimmunity with recombinant invariant chains in which CLIP is replaced by self-epitopes.

Authors:  F Bischof; W Wienhold; C Wirblich; G Malcherek; O Zevering; A M Kruisbeek; A Melms
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

3.  LAMP-2-deficient human B cells exhibit altered MHC class II presentation of exogenous antigens.

Authors:  Victoria L Crotzer; Nicole Glosson; Delu Zhou; Ichizo Nishino; Janice S Blum
Journal:  Immunology       Date:  2010-11       Impact factor: 7.397

4.  Small molecules that enhance the catalytic efficiency of HLA-DM.

Authors:  Melissa J Nicholson; Babak Moradi; Nilufer P Seth; Xuechao Xing; Gregory D Cuny; Ross L Stein; Kai W Wucherpfennig
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

5.  CD74 Deficiency Mitigates Systemic Lupus Erythematosus-like Autoimmunity and Pathological Findings in Mice.

Authors:  Yi Zhou; Huimei Chen; Li Liu; Xueqing Yu; Galina K Sukhova; Min Yang; Lijun Zhang; Vasileios C Kyttaris; George C Tsokos; Isaac E Stillman; Takaharu Ichimura; Joseph V Bonventre; Peter Libby; Guo-Ping Shi
Journal:  J Immunol       Date:  2017-02-20       Impact factor: 5.422

6.  Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM.

Authors:  A B Vogt; H Kropshofer; G Moldenhauer; G J Hämmerling
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

Review 7.  Selection of the MHC class II-associated peptide repertoire by HLA-DM.

Authors:  S O Arndt; A B Vogt; G J Hämmerling; H Kropshofer
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

8.  A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules.

Authors:  H Kropshofer; A B Vogt; C Thery; E A Armandola; B C Li; G Moldenhauer; S Amigorena; G J Hämmerling
Journal:  EMBO J       Date:  1998-06-01       Impact factor: 11.598

9.  Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers.

Authors:  Cheryl L Day; Nilufer P Seth; Michaela Lucas; Heiner Appel; Laurent Gauthier; Georg M Lauer; Gregory K Robbins; Zbigniew M Szczepiorkowski; Deborah R Casson; Raymond T Chung; Shannon Bell; Gillian Harcourt; Bruce D Walker; Paul Klenerman; Kai W Wucherpfennig
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

10.  Identification of Streptococcus mutans PAc peptide motif binding with human MHC class II molecules (DRB1*0802, *1101, *1401 and *1405).

Authors:  H Senpuku; K Yanagi; T Nisizawa
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.